Comparative Effectiveness In U.S. Will Not Be NICE, OMB’s Orszag says
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. will not follow the UK’s model of having a bureaucratic organization making cost-effectiveness decisions, OMB director tells Congress.
You may also be interested in...
Cost Effectiveness Decisions Playing Greater Role In Off-Label Coverage
The role of cost analysis in the context of comparative effectiveness research has been hotly contested, but cost effectiveness is already gaining importance as a factor in how third-party payers run Medicare and Medicaid prescription drug plans
Cost Effectiveness Decisions Playing Greater Role In Off-Label Coverage
The role of cost analysis in the context of comparative effectiveness research has been hotly contested, but cost effectiveness is already gaining importance as a factor in how third-party payers run Medicare and Medicaid prescription drug plans
CMS Authority For Least Costly Alternative On Drugs Coming Soon – Sen. Roberts
Kansas senator expresses concern that LCA authority, combined with comparative effectiveness, could blur the lines between FDA and CMS.